Clinical trials: Monoclonal
Solid Tumors
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited.
- Trial name
- NCT05522582
- Testing
- Methotrexate tablets, Anti-PD-1 monoclonal antibody, Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yancheng First People's Hospital
Lymphoma, Non-Hodgkin Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas.
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT03223610
- Testing
- Venetoclax, Ibrutinib, Prednisone
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
- Trial name
- NCT00816361
- Testing
- MEDI-573
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- MedImmune LLC
Sepsis-Induced Hypotension
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving…
- Trial name
- ESTELLA (NCT06608901)
- Testing
- REGN7544, PB
- Where
- 29 sites in United States, France
- Volunteers
- 76 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of…
- Trial name
- NCT04045795
- Testing
- isatuximab SAR650984 IV, pomalidomide, dexamethasone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 56 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
- Trial name
- PROTECT (NCT03875729)
- Testing
- teplizumab
- Where
- 62 sites in United States, Belgium and 7 more
- Volunteers
- 328 people
- Sponsor
- Provention Bio, Inc.
Healthy Adult Male
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
The aim of this study is to establish comparability of pharmacokinetic parameters and similarity of the safety and immunogenicity profiles of single subcutaneous doses of BCD 057 100 mg/mL and BCD-057 50 mg/mL, as well as BCD-057…
- Trial name
- NCT07181694
- Testing
- Adalimumab (BCD-057) 100 mg/mL, Adalimumab (BCD-057) 50 mg/mL, Adalimumab (Humira) 100 mg/mL
- Where
- 4 sites in Russia
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- Biocad
Quality of Life (QOL), CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study for the Evaluation of the Degree of Skin Satisfaction of a Cosmetic Cream for Sensitive Skin in Oncological Patients Affected by a Palmoplantar Polyneuropathy Secondary to Chemotherapy.
It is proposed a controlled research study aimed to evaluating and comparing the degree of skin satisfaction and comfort with cosmetic creams PB-011 and PB-012 in cancer patients who can develop a palmar and plantar peripheral…
- Trial name
- NCT06733545
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- PROSPERA BIOTECH S.L.
Multiple Myeloma, Smoldering Myeloma
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.
- Conditions
- Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT00919139
- Testing
- biologic sample preservation procedure
- Where
- 207 sites in United States
- Volunteers
- 190 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Ductal Adenocarcinoma, PDAC
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low.
- Trial name
- NCT05201729
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Cancer, Neoplasms
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Human Epidermal Growth Factor Receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis.
- Trial name
- NCT01966445
- Testing
- GSK2849330
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Safety Tolerability and Pharmacokinetics of ALD403
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT01579383
- Testing
- ALD403, Sumatriptan
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Alder Biopharmaceuticals, Inc.
Liver Cancer
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00410956
- Testing
- bevacizumab, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Phase 1 To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 2 To evaluate the…
- Trial name
- NCT04425629
- Testing
- casirivimab+imdevimab combination therapy
- Where
- 114 sites in United States, Mexico and 1 more
- Volunteers
- 10,078 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX22 in patients with advanced solid tumors overexpressing HER2 after failure of standard of care.
- Trial name
- NCT03916094
- Testing
- HLX22
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shanghai Henlius Biotech
Lower Respiratory Tract Infection, Respiratory Syncytial Virus Infections
Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
The purpose of this study is to determine the utilization patterns and compliance rates of palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial virus infection.
- Trial name
- NCT00420966
- Where
- 2 sites in Canada
- Volunteers
- 25,003 people
- Sponsor
- Sunnybrook Health Sciences Centre
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire
NSCLC, Locally Advanced
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced…
- Trial name
- TRIPL (NCT06865339)
- Testing
- Cemiplimab, Fianlimab, Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Montefiore Medical Center
Metastatic Colorectal Cancer
Pharmacokinetics and Metabolic Activation of Capecitabine
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).
- Trial name
- NCT01579357
- Testing
- blood samples
- Where
- 3 sites in Austria
- Volunteers
- 24 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.